Table 1 Demographics and baseline characteristics of COPD patients

Age, years (range)

67.9 (48-81)

69.5 (46-86)

0.402

Gender, males %

60.3

56.8

0.723

Current smokers, n (%)

15 (28.3)

13 (29.5)

0.471

Smoking history (Pack-years), mean (SD)

53.10 (23.83)

48.87 (34.1)

0.080

Severity of COPD – GOLD Stage

0.109

I (FEV₁ ≥ 80 % predicted), n

6

2

II (50 % predicted ≤ FEV₁ ≤ 80 % predicted), n

20

14

III (30 % predicted ≤ FEV₁ ≤ 50 % predicted), n

14

21

IV (FEV₁ ≤ 30 % predicted), n

13

6

VC % predicted (SD)

89.6 (21.4)

87.7 (17.8)

0.658

FEV₁ % predicted (SD)

50.3 (21.5)

48.0 (15.9)

0.543

FEV₁/VCmax (SD)

43.3 (13.7)

43.8 (13.7)

0.846

TLC % predicted (SD)

114.7 (22.3)

111.9 (20.0)

0.721

RV % predicted (SD)

162.8 (61.5)

157.6 (45.1)

0.290

DLCO % predicted (SD)

48.3 (19.2)

45.7 (18.3)

0.507

RV/TLC (SD)

0.55 (0.11)

0.56 (0.09)

0.988

paO₂, kPa (SD)

8.8 (1.5)

9.2 (1.5)

0.294

paCO₂, kPa (SD)

5.3 (0.8)

5.2 (0.8)

0.399

HbCO % (SD)

2.6 (2.5)

2.2 (2.1)

0.414

CT scan assessment, n

29

32

Bronchiectasis

4

7

Moderate emphysema

9

10

Severe emphysema

17

17

COPD-medication, n (%)

SABA

11 (21)

10 (23)

0.768

LABA

7 (13)

5 (11)

0.816

LAMA

8 (15)

14 (32)

0.043

SABA + LAMA

10 (19)

12 (28)

0.295

LABA + ICS

37 (70)

28 (65)

0.625

ICS

3 (6)

5 (12)

0.460

oral corticosteroids

18 (34)

19 (44)

0.306

Xanthines

2 (4)

1 (2)

1.000

Mucolytics

5 (9)

11 (26)

0.035

LTOT

11 (21)

12 (28)

0.414